secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2025-03-12T23:59:59+00:00
Accession:  0001171843-25-001437
Event type: earnings
Sentiment:  neutral
Materiality: 0.72
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Therapeutics reports Q4 2024 revenue $30.6M, full year $119.9M; guides 2025 adj EBITDA margin 8-10%
--------------------------------------------------------------------------------

- Q4 revenue from continuing ops $30.6M (+1% YoY); full-year revenue $119.9M (-1% YoY).
- Commercial Channel revenue up 25% in Q4 ($10.9M) and 17% for full year ($42.1M).
- Net loss from continuing ops: Q4 ($2.5M), ($0.17)/share; FY ($8.8M), ($0.60)/share.
- FY 2025 guidance: Commercial Channel $47-49.5M (+12-18%), OEM Channel $64-68.5M (-12-18%).
- Sale of Parcus Medical completed Mar 7; $5.6M in stock repurchased in Q4, $15M plan completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184325001437/0001171843-25-001437-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184325001437/f8k_031225.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001437

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer